Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by stock analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a note issued to investors on Wednesday. The analysts noted that the move was a valuation call.
AGIO has been the topic of a number of other reports. Credit Suisse Group upped their price target on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Zacks Investment Research raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 price target on the stock in a report on Tuesday, January 16th. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 12th. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $77.64.
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded up $1.44 during trading hours on Wednesday, hitting $77.97. The stock had a trading volume of 1,075,108 shares, compared to its average volume of 842,112. The company has a market capitalization of $3,800.00, a P/E ratio of -12.44 and a beta of 2.12. Agios Pharmaceuticals has a 1 year low of $45.11 and a 1 year high of $82.96.
In other news, CEO David P. Schenkein sold 53,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $73.16, for a total value of $3,877,480.00. Following the completion of the transaction, the chief executive officer now owns 53,000 shares of the company’s stock, valued at $3,877,480. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Corp /De/ Celgene purchased 851,154 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were purchased at an average cost of $67.00 per share, with a total value of $57,027,318.00. Following the completion of the purchase, the insider now owns 1,374,599 shares of the company’s stock, valued at approximately $92,098,133. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 183,114 shares of company stock valued at $13,866,025. Corporate insiders own 5.43% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. QS Investors LLC bought a new position in Agios Pharmaceuticals during the second quarter valued at approximately $144,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Agios Pharmaceuticals by 41.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 762 shares during the last quarter. State of Alaska Department of Revenue bought a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $160,000. Cubist Systematic Strategies LLC boosted its stake in Agios Pharmaceuticals by 1,041.0% during the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,123 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 1,520 shares during the last quarter. 82.74% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Agios Pharmaceuticals (AGIO) Stock Rating Lowered by Oppenheimer” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/14/agios-pharmaceuticals-agio-stock-rating-lowered-by-oppenheimer.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.